New Delhi, Sep 26 (IANS) India is on the cusp of a transformative era in its pharmaceutical sector which is projected to reach $130 billion by 2030, a report showed on Thursday.
The world’s third-largest drug producer by volume, India is currently exporting pharmaceutical products to over 200 countries, establishing its influence in the global pharmaceutical arena, according to a Deloitte’s whitepaper launched at the Assocham’s annual pharma summit here.
The paper highlighted India’s potential to transform from a leading generic drug producer to a powerhouse of pharmaceutical innovation, driven by advancements in research, regulatory reforms, and strategic global partnerships.
“With the market projected to reach $130 billion by 2030, growth depends on significant investments in R&D and addressing talent shortages in areas like AI and biotechnology,” said Joydeep Ghosh, Partner and Industry Leader for Life Sciences and Healthcare at Deloitte India.
Government initiatives such as the production-linked incentive scheme aim to enhance domestic manufacturing and reduce reliance on imports.
“By fostering collaboration among academia, industry, and government, India can not only meet its healthcare needs but also position itself as a leader in global pharmaceutical innovation, driving economic growth and improving health outcomes,” Ghosh added.
As per the paper, with a growing talent pool, rising investments in biotechnology, and an increasing number of clinical trials, India is becoming a credible destination for cutting-edge drug discovery and development.
Government initiatives, collaborations between academia and industry, and advancements in digital technologies further bolster India’s potential to lead in pharmaceutical innovation.
However, the paper identified critical challenges that must be addressed to fully realise India’s potential as a global pharmaceutical innovation hub.
“Key issues include the need for increased investment in R&D, stronger intellectual property protections, and the closing of the talent gap in high-demand areas such as artificial intelligence and data science,” the paper noted.
To foster a robust innovation ecosystem, it is crucial to develop a cohesive strategy that integrates research, technology investments, commercialization, skilling, and intellectual property, commented Neha Aggarwal, Partner, Deloitte India.
–IANS
na/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
